99mTc-fanolesomab Palatin Technologies.
99mTc-fanolesomab is a radiolabeled imaging agent which is being developed by Palatin Technologies for use in the diagnosis of various infections, including appendicitis and osteomyelitis.
Long Island Jewish Medical Center, Division of Nuclear Medicine, 270-05 76th Avenue, New Hyde Park, NY 11040, USA.
Charito
C
Love
Christopher J
CJ
Palestro
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics; D002986:Clinical Trials as Topic; D006801:Humans; D007239:Infections / Q000175:diagnosis; D007275:Injections, Intravenous; D016256:Lewis X Antigen / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics; D013329:Structure-Activity Relationship; D013667:Technetium
D000911:Antibodies, Monoclonal; D016256:Lewis X Antigen; D019275:Radiopharmaceuticals; D013667:Technetium; C414128:techneticum TC-99M fanolesomab